(Adnkronos) - “Per una paziente su 3 con tumore al seno in fase inziale si riduce il rischio di recidiva”. A dirlo è Michelino De Laurentiis, direttore del Dipartimento di Oncologia senologica e toraco-polmonare, Istituto nazionale tumori Irccs Fondazione 'G. Pascale' di Napoli in occasione del Congresso 2024 della European Society for Medical Oncology (Esmo) di Barcellona. “La terapia mirata con ribociclib (due compresse al giorno per 36 mesi) aggiunta alla terapia endocrina (Et) – spiega l’oncologo - mostra un consistente beneficio dopo 3 anni di trattamento, riducendo il rischio di recidiva del 28,5% rispetto alla sola Et, nei pazienti con tumore della mammella in stadio iniziale II e III positivo per i recettori ormonali e negativo per il recettore 2 del fattore umano di crescita epidermica (Hr+/Her2-)”.
Category
🗞
NewsTranscript
00:00We are at the ESMO Congress in Barcelona, the most important oncology congress in Europe and one of the most important in the world.
00:08We have just witnessed the publication and presentation of the results updated four years ago of the NATALI study.
00:17What is the NATALI study?
00:18It is a study that has predicted the addition of a new drug to hormone therapy,
00:24the standard treatment that we have been doing for years for women with breast cancer.
00:31Ribociclib, which is the dose of two compresses a day for three years,
00:36added to hormone therapy has produced further improvement in the risk of these patients,
00:41reducing the risk of the disease, the so-called recidivism, by about 28.5%.
00:49It even reaches 34.4% in women at a lower risk, that is, those without metastasis and lymph nodes.
00:57What is the good news?
00:59The good news is that now these results are very mature and stable,
01:04therefore directly transferable in clinical practice as soon as the drug is available,
01:09and since there is a tendency to improve with the maturation of the data,
01:14it is possible that they will mature, improving further in the coming years.
01:18So it is really good news for women with breast-operated hormone-sensitive tumors,
01:25because the foundations are laid for an improvement of the recovery rates.